254 related articles for article (PubMed ID: 38111706)
1. Predictive markers for anti-inflammatory treatment response in thyroid eye disease.
Zhang H; Fan J; Qu J; Han Q; Zhou H; Song X
Front Endocrinol (Lausanne); 2023; 14():1292519. PubMed ID: 38111706
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease.
Ayabe R; Rootman DB; Hwang CJ; Ben-Artzi A; Goldberg R
Ophthalmic Plast Reconstr Surg; 2014; 30(5):415-9. PubMed ID: 24978425
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.
Poon SHL; Cheung JJ; Shih KC; Chan YK
Rev Endocr Metab Disord; 2022 Jun; 23(3):541-567. PubMed ID: 35066781
[TBL] [Abstract][Full Text] [Related]
4. Future Projections in Thyroid Eye Disease.
Barbesino G; Salvi M; Freitag SK
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
[TBL] [Abstract][Full Text] [Related]
5. Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids.
Xu N; Cui Y; Fu D; Sun F
J Endocrinol Invest; 2020 Jul; 43(7):901-910. PubMed ID: 31927748
[TBL] [Abstract][Full Text] [Related]
6. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
[TBL] [Abstract][Full Text] [Related]
7. Novel inflammatory biomarkers in thyroid eye disease.
Ueland HO; Ueland GÅ; Løvås K; Breivk LE; Thrane AS; Meling Stokland AE; Rødahl E; Husebye ES
Eur J Endocrinol; 2022 Aug; 187(2):293-300. PubMed ID: 35675127
[TBL] [Abstract][Full Text] [Related]
8. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
Kossler AL; Douglas R; Dosiou C
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory and Noninflammatory Thyroid Eye Disease: Comparison of Disease Signs, Symptoms, and Quality of Life in Patients in the United States.
Wang Y; Padnick-Silver L; Francis-Sedlak M; Holt RJ; Foley C; Douglas RS
Endocr Pract; 2022 Sep; 28(9):842-846. PubMed ID: 35714862
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab-Induced Thyroid Eye Disease: A Comprehensive Case Series and Review of the Literature.
Nirmalan A; Blecher N; Hyder S; Couch SM; Godfrey KJ; Stan MN; Bradley EA; Wagner LH; Tooley AA
Ophthalmic Plast Reconstr Surg; 2023 Sep-Oct 01; 39(5):470-474. PubMed ID: 36893061
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab for thyroid eye disease.
Hamed Azzam S; Kang S; Salvi M; Ezra DG
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012984. PubMed ID: 30480323
[TBL] [Abstract][Full Text] [Related]
12. Teprotumumab: A Review in Thyroid Eye Disease.
Nie T; Lamb YN
Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
[TBL] [Abstract][Full Text] [Related]
13. Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach.
Sipkova Z; Insull EA; David J; Turner HE; Keren S; Norris JH
Clin Endocrinol (Oxf); 2018 Dec; 89(6):834-839. PubMed ID: 30103255
[TBL] [Abstract][Full Text] [Related]
14. The eye and thyroid disease.
Kuriyan AE; Phipps RP; Feldon SE
Curr Opin Ophthalmol; 2008 Nov; 19(6):499-506. PubMed ID: 18854695
[TBL] [Abstract][Full Text] [Related]
15. Molecular Biomarkers in Thyroid Eye Disease: A Literature Review.
Ueland HO; Neset MT; Methlie P; Ueland GÅ; Pakdel F; Rødahl E
Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S19-S28. PubMed ID: 38054982
[TBL] [Abstract][Full Text] [Related]
16. [Monoclonal antibodies in the treatment of thyroid eye disease].
Cheredanova VR; Poteshkin YE
Vestn Oftalmol; 2021; 137(4):116-122. PubMed ID: 34410066
[TBL] [Abstract][Full Text] [Related]
17. Circulating miR-146a predicts glucocorticoid response in thyroid eye disease.
Manso J; Censi S; Clausi C; Piva I; Zhu YH; Mondin A; Pedron MC; Barollo S; Bertazza L; Midena G; Parrozzani R; Mian C
Eur Thyroid J; 2023 Oct; 12(5):. PubMed ID: 37606076
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
19. Severity of thyroid eye disease and type-2 diabetes mellitus: Is there a correlation?
Ramamurthy LB; Rangarajan V; Srirao N; Malini B; Bansal R; Yuvarajan K
Indian J Ophthalmol; 2020 Jun; 68(6):1127-1131. PubMed ID: 32461446
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease.
Young SM; Lim AYN; Lang SS; Lee KO; Sundar G
Orbit; 2019 Oct; 38(5):362-369. PubMed ID: 30540214
[No Abstract] [Full Text] [Related]
[Next] [New Search]
